Coherus Oncology reports annual meeting results

Coherus Oncology (CHRS) held its annual stockholder meeting, electing three Class II directors (O’Donnell-Tormey, Ryan, and Satvat) and ratifying Ernst & Young as its auditor for fiscal year 2025. The proposals, including an advisory vote on executive compensation and an amendment to the employee stock purchase plan, were approved, reflecting stockholder decisions on company governance. These governance decisions come as analysts anticipate a sales decline and have recently revised earnings downward, while the company focuses on the launch of Lactorzi and expansion of its market presence after a challenging Q1.

Analysis

Coherus Oncology's annual stockholder meeting on June 11, 2025, where 75,584,254 out of 115,922,573 outstanding shares were represented, resulted in the election of three Class II directors: Jill O’Donnell-Tormey, Michael Ryan, and Ali J. Satvat, each securing a majority of votes cast, though Satvat received a notable 11,168,208 withheld votes against 27,759,763 for. Ernst & Young LLP was ratified as the independent auditor. A non-binding advisory resolution on executive compensation was approved with 19,179,927 votes for versus 16,164,644 against, indicating considerable shareholder dissent, especially when considering the 3,583,400 abstentions and 36,656,283 broker non-votes, the latter figure also applying to director elections and the approved amendment to the Employee Stock Purchase Plan. These governance outcomes unfold against a backdrop of analyst expectations for a sales decline in the current year and recent downward earnings revisions for Coherus. The company's Q1 2025 earnings revealed flat revenue at $7.3 million, despite a 15% rise in patient demand. Strategically, Coherus completed the divestiture of UDENYCA for $483 million, anticipates $25 million in annualized savings from headcount reductions, and launched Lactorzi, a PD-1 inhibitor for nasopharyngeal carcinoma, with an ambitious sales projection of $150-200 million annually within three years. However, the stock declined post-earnings, reflecting investor apprehension over future earnings potential and negative EPS forecasts for upcoming quarters, contributing to an overall moderately negative sentiment for the company.

Key Decisions for Investors

• Investors should closely monitor Lactorzi's market penetration and sales ramp-up, as its success is pivotal to Coherus's financial turnaround amidst projected declines in existing revenue streams and negative earnings forecasts.
• The significant minority vote against executive compensation and the high proportion of withheld votes for one director, coupled with substantial broker non-votes across key proposals, signal potential shareholder dissatisfaction that warrants careful consideration of governance risks.
• Given the anticipated sales decline, downward earnings revisions, and negative EPS outlook, a cautious stance is advisable; investors should scrutinize cash burn, the progress of cost-saving initiatives, and the timeline to profitability driven by new product commercialization.
• Evaluate the company's transition strategy following the UDENYCA divestiture, focusing on its ability to effectively reallocate capital towards Lactorzi and other pipeline developments while navigating a challenging financial environment.